As the global 505(b)(2) experts, Camargo specializes in developing and delivering a faster,  lower cost, and lower risk program.

Identify Viable Products

Camargo has a disciplined approach to evaluating the scientific, medical, regulatory and commercial aspects of your product development opportunities to make correct go/no-go decisions throughout your project.

Develop Viable Products

With our integrated approach, the team at Camargo manages every facet of your program, from formulation and testing of the drug product to conducting nonclinical and clinical studies, to final FDA submission.

Regulatory Strategy

After more than a decade, Camargo Pharmaceutical Services has established something unrivaled in terms of 505(b)(2) investigational new drug (IND) and new drug application (NDA) preparation and submission.

Why Go With Camargo?

If you’re looking to reposition an existing product or expand your portfolio with a differentiated product, the 505(b)(2) approval pathway is your best way forward, and Camargo is your ideal partner. As the leader in 505(b)(2), we’re your go-to for identifying commercially viable products and executing faster, more cost-effective development from concept to commercialization.

We have the largest percentage of 505(b)(2) submissions.

We have guided more than 200 FDA NDA and ANDA approvals.

We routinely hold three to six pre-IND meetings a month.

We work across more than 25 countries worldwide.

What Our Clients Are Saying

Learn more about what it’s like to work with the team at Camargo.

We’re impressed by the quality and thoroughness of the submission package … we want to engage you on another product, not just the Pre-IND but all the way through NDA.

VP, R&D Biotech

The text from the gap analysis has a fair and balanced perspective and provides substantial insights we have not yet considered for our drug development strategy.

R&D Director, Biotech

Conferences and Events

Here are a few of the conferences and events the Camargo team will be attending and participating in this year. Hope to see you there.

The Latest from the Blog

Read the latest insights and information from our 505(b)(2) blog.